World Health Organization, Geneva, Switzerland.
Clinton Health Access Initiative, Boston, Massachusetts, United States of America.
PLoS One. 2019 Nov 21;14(11):e0225393. doi: 10.1371/journal.pone.0225393. eCollection 2019.
Expanding access to HIV viral load testing is essential to improving the care and treatment of people living with HIV/AIDS and ending the AIDS epidemic. Though significant investments have been made in the past five years, many high burden, low resource countries continue to have viral load access rates below 50%. Plasma preparation tubes (PPTs) can simplify storage, transport, and preparation of plasma used for viral load testing. A systematic review was conducted to evaluate the accuracy of plasma preparation tubes for HIV viral load testing. Study results regarding the accuracy of PPT viral load measurements across various storage and transportation conditions were examined. The quality of evidence was evaluated using GRADE and QUADAS-2 criteria. The review identified 16 studies using PPTs with data from 6,141 individuals from 1995 to 2014. Overall the quality of evidence was rated as moderate, with unclear applicability for studies evaluating viral load assays that are no longer commercially available. Significantly elevated viral load results (>0.3 log copies/ml difference) have been observed with PPTs; however, when manufacturer handling instructions are followed, when plasma is aliquoted into a secondary tube, or when PPTs are centrifuged prior to testing, PPT results only differed from standard EDTA plasma testing using commercially available viral load assays by a range on average of -0.03 to +0.08 log copies/ml across studies. Although spuriously elevated viral load results have been observed with PPTs, following proper sample handing techniques have been shown to provide accurate results. PPTs, therefore, provide a high quality alternative specimen type for countries seeking solutions to infrastructure and specimen transportation challenges in an effort to scale-up viral load testing and achieve 90-90-90 targets.
扩大艾滋病毒病毒载量检测的可及性对于改善艾滋病毒感染者和艾滋病患者的护理和治疗以及终结艾滋病疫情至关重要。尽管过去五年中投入了大量资金,但许多高负担、低资源国家的病毒载量检测可及率仍低于 50%。血浆准备管(PPT)可以简化用于病毒载量检测的血浆的储存、运输和准备。系统评价评估了 PPT 在艾滋病毒病毒载量检测中的准确性。研究结果检查了 PPT 病毒载量测量在各种储存和运输条件下的准确性。使用 GRADE 和 QUADAS-2 标准评估证据质量。该综述确定了 16 项使用 PPT 的研究,涉及 1995 年至 2014 年期间来自 6141 个人的数据。总体而言,证据质量被评为中等,对于评估不再商业化的病毒载量检测的研究,适用性不明确。使用 PPT 观察到显著升高的病毒载量结果(>0.3 log 拷贝/ml 差异);然而,当遵循制造商的处理说明、将血浆分装到第二管中或在测试前离心 PPT 时,PPT 结果仅与使用商业上可用的病毒载量检测的标准 EDTA 血浆检测相差 0.03 至 0.08 log 拷贝/ml。尽管使用 PPT 观察到虚假升高的病毒载量结果,但已证明遵循适当的样本处理技术可以提供准确的结果。因此,PPT 为寻求解决基础设施和标本运输挑战的国家提供了高质量的替代标本类型,以扩大病毒载量检测并实现 90-90-90 目标。